Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00258960
Recruitment Status : Completed
First Posted : November 28, 2005
Last Update Posted : September 28, 2009
Information provided by:
Spanish Breast Cancer Research Group

Brief Summary:

Eligible patients must receive Caelyx plus Cyclophosphamide plus Herceptin for 6 cycles that will be administered every 4 weeks.

Sample size calculation will be done by means of Simon's method in 2 stages for phase II studies and will be based on the principal aim of the study (evaluation of the rate of objective response).

The hypothesis brings over of the efficiency of the treatment it will be accepted if a rate of objective response of at least 55 % is obtained, rejecting the efficiency of the treatment when the rate of response targets be lower than 35 %. In this case, considering an alpha error of 0.05 and 80 % power, 14 patients will be included in the first stage; the study would continue if more than 5 objective responses were found. The total number of patients to including in the study would be 44. The results will be significant if they find at least 20 objective responses.

Assuming a drop-out rate of 10 %, the total number of patients needed is 49 patients.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Liposomal Doxorubicin Drug: Cyclophosphamide Drug: Trastuzumab Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 49 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase IV.II, Clinical Trial, With the Combination of Pegylated Liposomal Doxorubicin (Caelyx), Cyclophosphamide and Trastuzumab (Herceptin) in Patients With Metastatic Breast Cancer With Overexpression of HER2/Neu
Study Start Date : February 2006
Actual Study Completion Date : July 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Primary Outcome Measures :
  1. To evaluate objective response rate

Secondary Outcome Measures :
  1. To evaluate the profile of toxicity
  2. To evaluate time to progression
  3. To evaluate overall survival
  4. To determinate duration of response
  5. To determinate time to failure of treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must sign an informed consent before of especific procedures of clinical trial.
  • Patients with histologically confirmed breast cancer and overexpression of Her2neu.
  • Age> 18 years.
  • ECOG equal or < 2.
  • Patients have not been treated previously with chemotherapy for metastatic disease.
  • Patients must have at least one measurable lesion according to RECIST criteria.
  • Patients should have an adequate organ function to tolerate chemotherapy.

Exclusion Criteria:

  • Patients with hypersensitivity reactions to any of the medications of the clinical trial.
  • Patients who are pregnant or lactating are not eligible.
  • Hepatic disease.
  • Not controlled active infection
  • Symptomatic metastatic brain cancer
  • Previous adyuvant treatment with antrhacyclines with a total accumulated dose > 300 mg/m2 (Doxorubicin) or > 600 mg/m2 (Epirubicin)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00258960

GEICAM (Spanish Breast Cancer Research Group)
San Sebastián de los Reyes, Madrid, Spain, 28703
Sponsors and Collaborators
Spanish Breast Cancer Research Group
Study Chair: Miguel Martín, MD., PhD Spanish Breast Cancer Reserach Group

Additional Information: Identifier: NCT00258960     History of Changes
Other Study ID Numbers: GEICAM/2004-05
First Posted: November 28, 2005    Key Record Dates
Last Update Posted: September 28, 2009
Last Verified: September 2009

Keywords provided by Spanish Breast Cancer Research Group:
HER2 positive breast cancer
Metastatic breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Liposomal doxorubicin
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors